Comparison of stage III mucinous and serous ovarian cancer: a case-control study

Creative Commons License

Cuylan Z. F., KARABÜK E., Oz M., Turan A. T., Meydanli M. M., TAŞKIN S., ...Daha Fazla

JOURNAL OF OVARIAN RESEARCH, cilt.11, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 11
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1186/s13048-018-0464-2
  • Dergi Adı: JOURNAL OF OVARIAN RESEARCH
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Analyses, survival, Epithelial ovarian cancer, Mucinous adenocarcinoma, Serous cystadenocarcinoma, RESIDUAL DISEASE, PROGNOSTIC-SIGNIFICANCE, CELL-TYPE, CARCINOMA, SURVIVAL, ADENOCARCINOMA, HISTOLOGY, WOMEN, CHEMOTHERAPY, SURGERY
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: The purpose of this case-control study was to compare the prognoses of women with stage III mucinous ovarian carcinoma (MOC) who received maximal or optimal cytoreduction followed by paclitaxel plus carboplatin chemotherapy to those of women with stage III serous epithelial ovarian cancer (EOC) treated in the similar manner.